5 Small Stocks That Can Shoot Higher in January
After a take-no-prisoners 2015 market, the “January Effect” could be a doozy in 2016. Here are our picks.
View ArticleBarrons.com Stock Picks Just Behind Index in '15
A second-half swoon in health care hurt our performance, and those three oil companies didn’t help either.
View ArticleOversold Novartis: Juicy Yield, $9 Billion Pipeline
The drug maker’s stock has fallen hard, but a comeback plan is in the works. Why shares could rise 20%.
View ArticleViacom Can Unlock Value And Deliver Gains of 30%
Chairman Sumner Redstone’s exit, a 7.4 P/E and a 3.5% yield make the entertainment giant’s stock a buy.
View ArticleGilead Way Oversold As Investors Flee Biotech
BioMarin also a bargain. The sector is now selling at a price/earnings to growth ratio of just 0.5.
View ArticleKroger: Innovative, Safe, And the Category Killer
The supermarket’s shares should beat the index for the fourth year in a row, thanks to outstanding execution.
View ArticleWhy Buffett's Berkshire Hathaway Is Undervalued
Warren Buffett would be “delighted” to repurchase shares at 1.2 times book value. They now fetch 1.3 times.
View ArticleA Safe Casino Bet: Icahn's Tropicana Entertainment
The thinly traded stock is much cheaper than its peers. Would Carl Icahn buy out minority shareholders?
View ArticleYahoo Investors Should Soon See a Payoff
Stock rises 3% on Tuesday amid optimism the Web pioneer will finally proceed with sale of its core business.
View Article5 Hot New Drugs and the Companies Making Them
Pfizer, Roche, and Anacor are among drug makers expecting FDA approval on the next potential blockbusters.
View ArticleEarnings Season: Expect Profits to Keep On Falling
With Alcoa set to report Monday, analysts expect earnings recession to continue. Big banks an opportunity?
View ArticleUnloved Electronic Arts Could Jump 25% This Year
The videogame maker is boosting margins as digital delivery replaces sales of discs.
View ArticleOversold Energy Additive Company Poised to Jump
Investors have dumped shares of Innospec despite record free cash, reliable revenue, and diversification.
View ArticleBarrons.com Stock Picks Outpace the Market
Stocks recommended by the site beat the market by almost two percentage points, or 22%.
View ArticleIllumina's Breakthroughs Could Send Stock Up 30%
Beyond its gene-sequencing core, the company is working with Jeff Bezos to develop a blood test for cancer.
View ArticleWhy You Should Follow Carl Icahn Into Allergan
With strong growth, a promising pipeline and a share buyback, the drug maker is undervalued.
View ArticleDanaher: Rock Solid Growth; Cut-Rate Price
Exceptional management, steady growth, and an upcoming spinoff make the conglomerate a buy.
View ArticleBaxter: Goldman, Loeb, Betting on a Turnaround
With a leaner operation and new CEO, the medical device company’s stock can rise 40% in 4 years.
View Article'Oversold' Gap Yields 4.5% Could Pop as Profit Rises
The struggling retailer’s stock has fallen by 60%, but is climbing again on early hints of a turnaround.
View ArticleBarrons.com Stock Picks Beating Market in 2016
Small-caps lead the way, while financials and health care detract. Over 12 months, we are lagging.
View Article
